NAMS - NASDAQ

NewAmsterdam Pharma Company N.V.

NAMS·NASDAQ

$32.67

+2.5%

HealthcareBiotechnology

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$3.82B

EPS-1.7500

P/E Ratio-18.67

Earnings Date08/05/2026

nams

Total Debt

Last Annual Value

202.00K

3-Year CAGR

17%

5-Year CAGR

10-Year CAGR

Adjust for Inflation

NewAmsterdam Pharma Company N.V. Competitors Analysis of Total Debt

NAMS · NASDAQ

Company	Total Debt	CAGR 3Y	CAGR 5Y	CAGR 10Y
NewAmsterdam Pharma Company N.V. NASDAQ:NAMS	202.00K	49.9%	1.6%	N/A
Immunovant, Inc. NASDAQ:IMVT	72.00K	-61.1%	-53.8%	N/A
Praxis Precision Medicines, Inc. NASDAQ:PRAX	110.00K	-64.7%	-52.0%	N/A
Viking Therapeutics, Inc. NASDAQ:VKTX	137.00K	-52.3%	36.4%	-27.2%
Arcellx, Inc. NASDAQ:ACLX	96.26M	-0.5%	N/A	N/A
Akero Therapeutics, Inc. NASDAQ:AKRO	36.46M	11.5%	88.9%	N/A
CG Oncology, Inc. Common stock NASDAQ:CGON	7.02M	89.6%	-14.2%	N/A
Crinetics Pharmaceuticals, Inc. NASDAQ:CRNX	48.54M	-2.1%	73.7%	72.2%
Kymera Therapeutics, Inc. NASDAQ:KYMR	82.25M	-1.0%	35.6%	N/A
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	451.49M	318.4%	6.8%	7.8%
Soleno Therapeutics, Inc. NASDAQ:SLNO	2.69M	88.3%	42.5%	N/A

NewAmsterdam Pharma Company N.V. Fair Value Envelope

NAMS · NASDAQ

Our analysis suggests that NAMS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $32.67, this represents a potential HIDDEN relative to our calculated worth for NewAmsterdam Pharma Company N.V..

HIDDEN

Intrinsic Value

Current Price: $32.67

Related Guides

Blog Categories

Continue your NAMS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.